HC Wainwright reiterated their buy rating on shares of Mural Oncology (NASDAQ:MURA – Free Report) in a research report released on Wednesday,Benzinga reports. The brokerage currently has a $18.00 price objective on the stock.
Mural Oncology Stock Performance
Shares of MURA opened at $3.90 on Wednesday. The company has a 50-day simple moving average of $3.86 and a 200-day simple moving average of $3.58. The firm has a market capitalization of $67.19 million, a P/E ratio of -0.43 and a beta of 3.66. Mural Oncology has a 52 week low of $2.87 and a 52 week high of $5.12.
Mural Oncology (NASDAQ:MURA – Get Free Report) last posted its quarterly earnings results on Tuesday, March 11th. The company reported ($2.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.96) by ($0.05). During the same period in the previous year, the business earned ($3.57) EPS. As a group, equities analysts forecast that Mural Oncology will post -7.54 earnings per share for the current year.
Institutional Inflows and Outflows
Mural Oncology Company Profile
Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.
Featured Stories
- Five stocks we like better than Mural Oncology
- What is Put Option Volume?
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- Options Trading – Understanding Strike Price
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- How to Short Nasdaq: An Easy-to-Follow Guide
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Receive News & Ratings for Mural Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mural Oncology and related companies with MarketBeat.com's FREE daily email newsletter.